Glucagon-like Peptide-1 Receptor Agonists and the Risk of Acute Kidney Injury: Alarming, or Not?
Dimitrios Patoulias, Aristi Boulmpou, Christodoulos Papadopoulos, Michael Doumas
Abstract
We read with interest the 2 case reports of acute kidney injury (AKI) associated with semaglutide use, described by Leehey et al,1 given the risks associated with AKI.2,3 In light of the reported kidney benefits of glucagon-like peptide-1 receptor agonists (GLP-1RAs),4,5 we investigated whether GLP-1RAs are associated with increased risk for AKI, pooling data from cardiovascular outcome trials that enrolled high- or very-high-risk individuals with type 2 diabetes mellitus.
Topics & Concepts
SemaglutideMedicineAcute kidney injuryKidney diseaseGlucagon-like peptide 1 receptorInternal medicineDiabetes mellitusScopusKidneyDulaglutideExenatideType 2 diabetesEndocrinologyMEDLINEReceptorLiraglutideAgonistLawPolitical scienceDiabetes Treatment and ManagementPotassium and Related DisordersChronic Kidney Disease and Diabetes